Chronic lymphocytic leukemia

F Caligaris-Cappio

doi:10.4081/hmr.v2i5.727

Articles

23 June 2009

Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008

https://doi.org/10.4081/hmr.v2i5.727

Chronic lymphocytic leukemia

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

PDF

213

Views

2549

Downloads

Authors

F Caligaris-Cappio

support@pagepress.org

Chronic Lymphocytic Leukemia (CLL) is characterized by the expansion of monoclonal CD5+ B lymphocytes that accumulate in lymphoid organs, bone marrow (BM) and peripheral blood (PB). Refined cytogenetic studies are documenting the clinical importance of genetic subtyping CLL. The CLL-specific gene alterations are gradually coming to light thanks to mouse models and to the discovery that microRNA (miRNA) genes frequently reside in hot spots for chromosomal abnormalities in CLL cells: as an miR-15a and miR-16-1 are located at 13q14.3. The emerging view is that the main genetic alterations of CLL entail the deregulation of specific microRNAs (miRNAs) that lead to transcriptional/posttranscriptional abnormalities.